PriceTargets.com logo

Pfenex - PFNX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$12.75 As of 10/1/2020 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for PFNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pfenex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PFNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PFNX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Pfenex in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $12.75.

This chart shows the closing price for PFNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Pfenex. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/14/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$13.00
8/14/2020William BlairDowngradeOutperform ➝ Market Perform
8/12/2020Truist FinancialDowngradeBuy ➝ Hold
8/11/2020JMP SecuritiesDowngradeOutperform ➝ Market Perform
6/15/2020OppenheimerBoost TargetOutperform$10.00 ➝ $15.00
6/1/2020OppenheimerBoost TargetOutperform$9.00 ➝ $10.00
5/12/2020SunTrust BanksLower TargetBuy$15.00 ➝ $13.00
5/10/2020OppenheimerReiterated RatingBuy$9.00
4/22/2020OppenheimerInitiated CoverageOutperform$9.00
2/14/2020SunTrust BanksInitiated CoverageBuy$18.00
12/18/2019JMP SecuritiesReiterated RatingBuy$19.00
10/24/2019Cantor FitzgeraldInitiated CoverageOverweight$20.00
10/11/2019William BlairReiterated RatingBuy
9/11/2019JMP SecuritiesBoost TargetOutperform$13.00 ➝ $17.00
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Pfenex logo
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $12.75
Low: $12.75
High: $12.75

50 Day Range

MA: N/A

52 Week Range

Now: $12.75
Low: $5.26
High: $14.00

Volume

N/A

Average Volume

503,865 shs

Market Capitalization

$437.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pfenex?

The following Wall Street sell-side analysts have issued stock ratings on Pfenex in the last year:
View the latest analyst ratings for PFNX.

What is the current price target for Pfenex?

0 Wall Street analysts have set twelve-month price targets for Pfenex in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pfenex in the next year.
View the latest price targets for PFNX.

What is the current consensus analyst rating for Pfenex?

Pfenex currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PFNX.

What other companies compete with Pfenex?

Other companies that are similar to Pfenex include Cybin, NGM Biopharmaceuticals, Kinnate Biopharma, Biopharmx and Aveanna Healthcare. Learn More about companies similar to Pfenex.

How do I contact Pfenex's investor relations team?

Pfenex's physical mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company's listed phone number is +1-858-3524400. The official website for Pfenex is www.pfenex.com. Learn More about contacing Pfenex investor relations.